Program
IPG11406
A development code. Also written as “IPG11406 tablet”.
Its studies are mostly in Lupus Nephritis · Colitis, Ulcerative · Inflammatory Bowel Diseases, led by Nanjing Immunophage Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Immunophage Biotech | 42 open or running | phase 2since Nov 26, 2024 | Dec 25, 2023 | Nov 20, 2028phase 2 · NCT07937501 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 25, 2023First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT06255834 · 66 enrolled · China
- Nov 26, 2024Phase 2 study in Lupus NephritisNCT06717815 · 24 enrolled · China
- Apr 10, 2026Phase 2 study in Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489 · 144 planned · China
- Nov 8, 2026Phase 2 study in Lupus NephritisNCT07937501 · 192 planned · China
Ahead
- Nov 20, 2028Primary completion: phase 2 study in Lupus NephritisNCT07937501
- Dec 1, 2028Primary completion: phase 2 study in Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07937501Lupus Nephritis · China | 2 | Not yet recruiting | Nov 20, 2028 | 192 |
| NCT07535489Moderately to Severely Active Ulcerative Colitis (UC) · China | 2 | Recruiting | Dec 1, 2028 | 144 |
| NCT06717815Lupus Nephritis · China | 2 | Completed | Jun 8, 2026 | 24 |
| NCT06255834Inflammatory Bowel Diseases · China | 1 | Completed | Dec 30, 2024 | 66 |
How it is read
Names in the registry
- “IPG11406”, 3 entries
- “IPG11406 tablet”, 1 entry
Codes read as this program: IPG11406.
Conditions, from the studies’ own filings
- Lupus Nephritis, 2 studies
- Colitis, Ulcerative, 1 study
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.